Malignant endocrine neoplasm
MONDO:0021069A malignant neoplasm affecting the endocrine glands. Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.
Also known as: endocrine neoplasm, Endocrine tumour, cancer of endocrine gland, endocrine cancer, endocrine gland cancer, endocrine neoplasm, malignant, malignant endocrine gland neoplasm, malignant endocrine gland tumor
5472 clinical trials for this condition and its sub-types, 17 tagged with Malignant endocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Malignant endocrine neoplasm
-
Liver cancer 254 trials · 1,700 incl. sub-types
5 sub-types
- Carcinoma of liver and intrahepatic biliary tract 36 trials · 1,455 incl. sub-types Sub-types →
- Biliary tract cancer 240 trials · 614 incl. sub-types Sub-types →
- Liver sarcoma 1 trial · 10 incl. sub-types Sub-types →
- Liver lymphoma 1 trial Sub-types →
- Calcifying nested epithelial stromal tumor of the liver 0 trials
-
Neuroendocrine carcinoma 106 trials · 744 incl. sub-types
12 sub-types
- Small cell carcinoma 26 trials · 542 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types Sub-types →
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Goblet cell carcinoma 2 trials
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
-
Thyroid cancer 166 trials · 328 incl. sub-types
3 sub-types
- Thyroid gland carcinoma 41 trials · 237 incl. sub-types Sub-types →
- Thyroid lymphoma 0 trials Sub-types →
- Thyroid sarcoma 0 trials Sub-types →
-
Thymus cancer 10 trials · 225 incl. sub-types
2 sub-types
- Thymus lymphoma 0 trials · 175 incl. sub-types Sub-types →
- Thymic carcinoma 41 trials · 44 incl. sub-types Sub-types →
-
Adrenal gland cancer 16 trials · 62 incl. sub-types
3 sub-types
- Adrenal carcinoma 34 trials · 52 incl. sub-types Sub-types →
- Malignant tumor of adrenal cortex 0 trials · 42 incl. sub-types Sub-types →
- Adrenal medulla cancer 0 trials · 11 incl. sub-types Sub-types →
-
Pineal gland cancer 0 trials · 19 incl. sub-types
3 sub-types
- Pineoblastoma 15 trials Sub-types →
- Malignant pineal area germ cell neoplasm 2 trials · 3 incl. sub-types Sub-types →
- Pineal gland astrocytoma 1 trial
-
Malignant tumor of parathyroid gland 2 trials · 6 incl. sub-types
1 sub-type
- Parathyroid gland carcinoma 4 trials
-
Pituitary cancer 2 trials · 4 incl. sub-types
4 sub-types
- Pituitary adenocarcinoma 3 trials Sub-types →
- Growth hormone-producing pituitary gland carcinoma 0 trials
- Pituicytoma 0 trials
- Pituitary blastoma 0 trials
-
Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types
2 sub-types
- Ovarian small cell carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ovarian large-cell neuroendocrine carcinoma 0 trials
-
Malignant carotid body paraganglioma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 676 trials in this tab.
-
Aortic graft used to rebuild windpipe in thyroid cancer surgery
Cure Not yet recruitingResearchers test a new surgical approach for thyroid cancer that has invaded the windpipe. They replace the affected section with a preserved aortic graft supported by a silicone stent. The goal is to remove all cancer and improve survival. The trial includes patients whose cance…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a single shot build a cancer army inside the body?
Cure Not yet recruitingThis trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…
Phase 1/2 • Sponsor: Umoja Biopharma • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill restore the Body's tumor suppressor to fight multiple cancers?
Cure Not yet recruitingThis trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…
Phase 1/2 • Sponsor: LG Chem • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
Cure Not yet recruitingThis phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…
Phase 2 • Sponsor: Kure Cells, INC • Aim: Cure
Last updated Jul 22, 2026 00:00 UTC
-
Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
Disease control Not yet recruitingResearchers are testing whether a liver-sparing form of chemoembolization, called partial TACE, can boost the anti-tumor effects of the drug lenvatinib in people with liver cancer that cannot be removed by surgery. The trial enrolls about 40 adults with hepatocellular carcinoma w…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive drug targets Hard-to-Treat thyroid cancer
Disease control Not yet recruitingThis study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …
Phase 1/2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Liver tumors targeted directly: old pump, new drug
Disease control Not yet recruitingThis trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can scans predict which liver cancer patients need extra local therapy?
Disease control Not yet recruitingResearchers are studying whether adding local treatments such as ablation, radiotherapy, or transarterial therapy to the drug combination atezolizumab plus bevacizumab helps certain patients with unresectable hepatocellular carcinoma live longer. The study uses medical records an…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody pair takes aim at advanced liver cancer in major trial
Disease control Not yet recruitingResearchers are testing whether a new combination of two antibodies, JS207 and JS007, works better than the standard first-line treatment of toripalimab plus bevacizumab for advanced liver cancer. The trial enrolls about 560 adults with liver cancer that cannot be removed by surg…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted pill be safely used for RET-Driven cancers in india?
Disease control Not yet recruitingResearchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Two-Drug combo targets Hard-to-Treat recurrent small cell lung cancer
Disease control Not yet recruitingResearchers are testing a combination of paclitaxel polymeric micelles and ivonescimab in adults with small cell lung cancer that has returned or stopped responding after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. The phase 2 trial aims to see how many participants'…
Phase 2 • Sponsor: Shaodong Hong • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental combo aims to tackle advanced liver cancer
Disease control Not yet recruitingThis study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…
Phase 1/2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Smartphone app and wearable sensor team up to catch infections early in cancer care
Disease control Not yet recruitingResearchers at Mayo Clinic are studying a remote monitoring program called SHIELD for cancer patients who are starting systemic therapy. Participants use a smartphone app to report symptoms and wear a small temperature sensor. The app and sensor send data to the medical record, w…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Saline barrier lets heat target liver tumors near the diaphragm
Disease control Not yet recruitingResearchers are studying whether microwave ablation, helped by a saline injection that separates the liver tumor from the diaphragm, is safe and effective for hepatocellular carcinoma. They compare this approach with surgical resection in patients whose single tumor is 5 cm or sm…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an oral drug that starves tumors help Hard-to-Treat cancers?
Disease control Not yet recruitingResearchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New immunotherapy combo put to the test in advanced liver cancer
Disease control Not yet recruitingResearchers are testing whether an experimental immunotherapy called ZG005, combined with bevacizumab, works better than the standard combination of sintilimab and bevacizumab for people with advanced hepatocellular carcinoma who have not yet received systemic treatment. The tria…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Targeted drug 3D185 put to the test against FGFR2-Altered bile duct cancer
Disease control Not yet recruitingResearchers are testing a drug called 3D185 in people with advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, whose tumors have changes in the FGFR2 gene. All participants have already received at least one other systemic cancer treatment that stopped working.…
Phase 2 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New chemo combo shows promise for tough lung cancer
Disease control Not yet recruitingThis Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can adding immunotherapy to standard cancer care be safe for indian patients?
Disease control Not yet recruitingThis trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…
Phase 4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo outperform standard care in aggressive lung cancer?
Disease control Not yet recruitingThis phase III trial compares an experimental combination of two drugs, QLC5508 and QL2107, against the current standard treatment (tislelizumab plus chemotherapy) as a first-line therapy for people with extensive-stage small cell lung cancer. The study enrolls adults who have no…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo keep Limited-Stage lung cancer at bay?
Disease control Not yet recruitingThis phase 2 trial tests whether combining an experimental drug called SHR-7787 with the immunotherapy adebrelimab can help people with limited-stage small cell lung cancer. The study enrolls adults aged 18 to 75 whose cancer has not progressed after standard chemotherapy and rad…
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can sound waves supercharge immunotherapy against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo aims to fight merkel cell cancer when immunotherapy fails
Disease control Not yet recruitingThis study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors and control advanced Merkel cell cancer in people whose disease has worsened after standard immunotherapy. About 31 adults with stage III or IV Merkel cell canc…
Phase 1/2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail targets rare liver cancer in 29-Patient trial
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…
Phase 2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can immune cell infusions help fight solid tumors?
Disease control Not yet recruitingThis trial tests a cell therapy called DC-CTL, made from a patient's own immune cells, combined with standard anti-tumor treatment. The goal is to see if this approach is safe and may help control solid tumors such as colorectal, esophageal, lung, liver, and breast cancer. About …
Sponsor: Zhengzhou Revo-Gene Technology Co., LTD • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…
Phase 3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a steroid given during pancreatic surgery prevent a dangerous leak?
Disease control Not yet recruitingThis trial tests whether giving hydrocortisone during and right after pancreatic surgery can lower the risk of a postoperative pancreatic fistula, a serious leak of digestive fluids. About 20 adults with pancreatic, duodenal, or bile duct cancer will be randomly assigned to recei…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug combo outperform standard care for aggressive lung cancer?
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug ZL-1310, when combined with an immunotherapy drug, can help people with extensive-stage small cell lung cancer live longer than those receiving standard chemotherapy plus immunotherapy. The study enrolls about 530 adults who …
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A personalized support system aims to close cancer care gaps for hispanic patients
Disease control Not yet recruitingThis trial tests whether a culturally grounded supportive care navigation program can reduce emergency room visits, hospitalizations, and urgent care use among Hispanic/Latinx patients receiving cancer treatment. Participants are randomly assigned to either usual care or the inte…
Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted pill shrink hard-to-treat bile duct cancers?
Disease control Not yet recruitingThis phase 2 trial tests whether daraxonrasib, an oral drug that targets cancers with a KRAS mutation, can shrink tumors in people with advanced biliary tract cancer that has progressed after first-line treatment. Participants take the drug once daily in 28-day cycles. The main g…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Smarter radiation planning aims to boost liver tumor attack while sparing healthy tissue
Disease control Not yet recruitingThis study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Anti-Inflammatory drug may boost cancer therapy in bile duct cancer
Disease control Not yet recruitingThis study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker …
Phase 1/2 • Sponsor: Shanghai 6th People's Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a daily mineral make liver cancer therapy work better?
Disease control Not yet recruitingThis trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…
Phase 2 • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a genetic trait stop chemotherapy from working? a trial aims to fix that
Disease control Not yet recruitingThis trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead…
Phase 1/2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cell therapy aims to wipe out lingering lymphoma before it returns
Disease control Not yet recruitingThis early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Ancient herbal mix could boost liver health in advanced cancer
Disease control Not yet recruitingThis trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…
Phase 2 • Sponsor: Xiang-Qian • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a triple drug attack stop liver cancer from coming back?
Disease control Not yet recruitingThis trial tests whether combining three treatment approaches can reduce the chance of liver cancer returning after surgery. People who had their liver cancer completely removed but showed signs of microvascular invasion, a risk factor for recurrence, will receive chemotherapy di…
Phase 4 • Sponsor: Zhai Wenlong • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Long-Acting immune booster help fight advanced solid tumours?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental virus therapy takes on Drug-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug cocktail aims to tame rare lung cancer
Disease control Not yet recruitingThis study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill outsmart mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…
Phase 1 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Donor cells join fight against advanced cancers
Disease control Not yet recruitingThis early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…
Phase 1/2 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take on stubborn lymphoma
Disease control Not yet recruitingThis study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Not yet recruitingThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Not yet recruitingThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can immune cells shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…
Phase 1 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental vaccine cocktail targets rare liver cancer in early trial
Disease control Not yet recruitingThis early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn childhood cancers
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can an Anti-Inflammatory drug make liver cancer immunotherapy safer?
Disease control Not yet recruitingThis phase II trial is testing whether adding tocilizumab, an anti-inflammatory drug, to a standard two-drug immunotherapy regimen can reduce severe immune-related side effects in people with advanced liver cancer. The study enrolls about 51 adults with hepatocellular carcinoma t…
Phase 2 • Sponsor: CHA University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Smartwatch-Guided prehab aims to boost pancreatic surgery recovery
Disease control Not yet recruitingThis trial tests whether a wearable device and a personalized prehabilitation program can help adults recover better after surgery for pancreatic cancer or related conditions. Participants will wear a monitor to track vital signs and activity, and follow a program of exercise, nu…
Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase 2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can Pre-Surgery rehab ease recovery from tumor bowel blockage?
Disease control Not yet recruitingThis trial tests whether a multimodal prehabilitation program—combining exercise, nutrition, and psychological support—can improve outcomes for patients with tumor-related bowel obstruction. Participants are randomly assigned to receive either this program plus postoperative immu…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug combo shrink liver tumors?
Disease control Not yet recruitingThis study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A nudge in time: could text reminders boost alcohol care for cancer patients?
Disease control Not yet recruitingThis trial tests whether simple reminders—sent to patients' phones and to their care teams—can increase the use of alcohol screening and brief counseling (SBIRT) during cancer care. About 315 adults with cancer across four clinics will take part, with some clinics using the remin…
Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can immune checkpoint drugs fight cancers beyond their approved uses?
Disease control Not yet recruitingThis phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Liver cancer trial aims to boost immunotherapy with targeted chemo
Disease control Not yet recruitingThis phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Action drug combo outsmart advanced liver cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a 'No-Touch' microwave technique match surgery for liver tumors?
Disease control Not yet recruitingThis study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
Disease control Not yet recruitingThis phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat GI cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…
Phase 1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart a rare and aggressive cancer?
Disease control Not yet recruitingThis clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A shield for bone marrow: can a drug stop Chemo's blood cell side effect?
Disease control Not yet recruitingThis trial tests whether a drug called trilaciclib can prevent myelosuppression — a drop in blood cell counts — caused by a type of chemotherapy known as topoisomerase I inhibitor antibody-drug conjugates (ADCs). About 96 cancer patients who are scheduled to receive these ADC dru…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a Triple-Drug cocktail turn inoperable liver cancer into a surgical target?
Disease control Not yet recruitingThis trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
AI-Powered surveillance may outsmart liver cancer recurrence
Disease control Not yet recruitingThis trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common allergy pill keep liver cancer from returning?
Disease control Not yet recruitingThis trial investigates whether ebastine, a widely used allergy medication, can reduce the risk of liver cancer returning after surgery. The study enrolls people with a specific high-risk tumor feature called tumor budding. All participants will take ebastine daily for a year, an…
Phase 4 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can matching drugs to tumor genes beat biliary cancer?
Disease control Not yet recruitingThis umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental combo aims to tackle Treatment-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a triple therapy shrink untreatable liver tumors?
Disease control Not yet recruitingThis study looks at whether combining the targeted drug donafenib with an immunotherapy drug and a liver-directed procedure (either chemoembolization or infusion chemotherapy) can help people with unresectable hepatocellular carcinoma — liver cancer that cannot be removed by surg…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a Two-Drug cocktail shrink Hard-to-Treat bile duct cancers?
Disease control Not yet recruitingThis trial is testing whether a combination of two drugs—sacituzumab tirumotecan and envafolimab—can shrink advanced biliary tract cancers (cancers of the bile ducts or gallbladder) that have grown despite initial treatment. The study enrolls up to 28 adults whose tumors carry a …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a gentler drug trio tame small cell lung cancer in older patients?
Disease control Not yet recruitingThis trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a diabetes drug help fight liver cancer? a trial puts it to the test
Disease control Not yet recruitingThis trial investigates whether adding dapagliflozin—a drug typically used for diabetes—to standard first-line therapy can improve tumor response in people with advanced liver cancer that cannot be surgically removed and who also have metabolic syndrome. About 44 participants wil…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
AI takes on liver cancer: could a computer help pick the right immunotherapy?
Disease control Not yet recruitingThis trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding zolbetuximab, an antibody that targets a protein called claudin 18.2, to standard chemotherapy can help control advanced or metastatic biliary tract cancers. The study enrolls adults whose tumors overexpress this protein. Participants …
Phase 2 • Sponsor: Midhun Malla • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gut bacteria transplant may supercharge liver cancer immunotherapy
Disease control Not yet recruitingThis trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug aims to shrink rare adrenal tumors
Disease control Not yet recruitingThis phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the dru…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase 1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Oral drug elraglusib aims to tame advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…
Phase 1/2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Triple immunotherapy cocktail aims to boost surgery success in liver cancer
Disease control Not yet recruitingThis phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study…
Phase 1/2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to tame aggressive lymphoma in frail patients
Disease control Not yet recruitingThis early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat gut tumors
Disease control Not yet recruitingThis phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could your own immune cells keep liver cancer from coming back?
Disease control Not yet recruitingThis trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intrav…
Early phase 1 • Sponsor: Royan Institute • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Sitting up for cancer treatment: a new way to deliver proton therapy
Disease control Not yet recruitingThis study explores whether cancer patients can safely receive proton radiation therapy while sitting upright instead of lying down. The upright system is already FDA-cleared, and the goal is to see if it works reliably for a range of patients. Researchers will track treatment su…
Sponsor: Stanford University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug hope for rare throat and thyroid cancers
Disease control Not yet recruitingThis study tests a drug called sacituzumab tirumotecan in people with two rare cancers: adenoid cystic carcinoma (a type of salivary gland cancer) and papillary thyroid carcinoma that have returned or spread. About 68 participants will receive the drug through an IV twice a month…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Targeted drug aims to shrink Hard-to-Treat bile duct cancers
Disease control Not yet recruitingThis phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with advanced biliary tract cancer whose disease has worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to seek out and deliver chemotherapy directly t…
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to shrink tough lung cancers
Disease control Not yet recruitingThis phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could adding chemo to tarlatamab overcome resistance in lung cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …
Phase 2 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy drug temozolomide under review for tough pituitary tumors
Disease control Not yet recruitingThis study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…
Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New PARP1 inhibitor targets Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …
Phase 1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Triple-Drug cocktail plus targeted procedure aims to tame incurable liver cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Double immune attack: new drug combo takes on advanced liver cancer
Disease control Not yet recruitingThis clinical trial is testing a combination of two experimental drugs, IMM2510 and IMM27M, in people with advanced hepatocellular carcinoma (a type of liver cancer) who have not yet received treatment for their advanced disease. The drugs are designed to help the immune system r…
Phase 2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Simple blood tests could spot liver cancer earlier in diabetics
Disease control Not yet recruitingThis study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental drug targets Hard-to-Treat neuroendocrine cancers
Disease control Not yet recruitingThis trial tests an experimental drug called CTX-471 in people with advanced neuroendocrine tumors that have a specific marker (NCAM) and have stopped responding to standard treatments. Participants receive the drug by IV every two weeks. The study aims to see if the drug can shr…
Phase 2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Pre-Surgery cocktail aims to boost liver cancer outcomes
Disease control Not yet recruitingThis study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then und…
Phase 2 • Sponsor: Affiliated Hospital of Guangdong Medical University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase 1/2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New combo attack on untreatable liver cancer shows promise in early trial
Disease control Not yet recruitingThis phase II trial is testing whether a combination of treatments can help people with a type of liver cancer that cannot be removed by surgery. The approach uses local chemotherapy delivered directly to the liver, along with immunotherapy (toripalimab) and a targeted therapy pi…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Triple-Drug attack aims to stop liver cancer recurrence after surgery
Disease control Not yet recruitingThis phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase 2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Smart nursing cuts kidney damage risk in liver cancer patients
Disease control Not yet recruitingThis study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo takes on advanced cancers
Disease control Not yet recruitingThis early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants acros…
Phase 1/2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Radiation and drug combo shows promise for tough liver cancers
Disease control Not yet recruitingThis study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…
Phase 4 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Liver cancer radiation therapy may open door to transplant
Disease control Not yet recruitingThis study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …
Phase 2 • Sponsor: Sirtex Medical • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
Disease control Not yet recruitingThis phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase 1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive microspheres aim to shrink stubborn liver tumors
Disease control Not yet recruitingThis study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can …
Phase 2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Scar-Free thyroid surgery could match traditional open surgery
Disease control Not yet recruitingThis study compares two surgical approaches for unilateral thyroid cancer: a newer, scar-free endoscopic technique through the armpit versus standard open neck surgery. Researchers will track complications, recovery time, and patient satisfaction in 400 adults aged 18-70 with ear…
Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for bile duct cancer: drug duo targets tough tumors
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve sur…
Phase 2 • Sponsor: HuiKai Li • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase 1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo may boost surgery success in returning liver cancer
Disease control Not yet recruitingThis study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingThis trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…
Phase 1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase 1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy before surgery shows promise for bile duct cancer
Disease control Not yet recruitingThis phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Radiation plus immunotherapy shows promise in bile duct cancer trial
Disease control Not yet recruitingThis study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to …
Phase 2 • Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…
Phase 2/3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims at resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase 2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to keep lung cancer at bay longer
Disease control Not yet recruitingThis study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…
Phase 3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase 1/2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase 1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New stent study aims to ease bile duct blockage in pancreatic cancer patients
Disease control Not yet recruitingThis study tests whether a newer, shorter metal stent works better than a standard plastic stent for opening blocked bile ducts in people with pancreatic cancer who need surgery. About 116 adults with operable or locally advanced pancreatic cancer and high bilirubin levels will b…
Sponsor: Soonchunhyang University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for liver cancer patients when immunotherapy stops working
Disease control Not yet recruitingThis phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Freeze-and-Heat attack: could a new device boost liver cancer treatment?
Disease control Not yet recruitingThis study tests whether adding a special thermal therapy (which freezes and heats tumors) to standard targeted therapy and immunotherapy can help people with advanced liver cancer that cannot be removed by surgery. About 166 participants will be randomly assigned to receive eith…
Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo aims to shrink bile duct tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectabl…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Which Pre-CAR-T chemo is safer? new trial aims to find out
Disease control Not yet recruitingThis trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
MRNA cancer shot shows promise in early trial
Disease control Not yet recruitingThis early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals…
Phase 1/2 • Sponsor: IntraAb, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Thyroid cancer surgery debate: to dissect or not to dissect neck nodes?
Disease control Not yet recruitingThis study looks at people with papillary thyroid cancer tumors 2 to 4 cm who are having thyroid surgery. Half will also have nearby neck lymph nodes removed, and half will not. The goal is to see if removing these nodes lowers the chance of cancer coming back or persisting, and …
Sponsor: Leonardo Rossi • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail of immunotherapy, targeted drug, chemo, and radiation takes on lung cancer
Disease control Not yet recruitingThis phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for advanced lung cancer: combo therapy targets tough tumors
Disease control Not yet recruitingThis study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for stroke patients with cancer: antioxidant drug trial launches
Disease control Not yet recruitingThis study tests whether a drug called edaravone dexborneol can help people who have a stroke while also having active cancer. The drug is given by IV twice a day for 10-14 days. Researchers will check if it improves recovery and is safe. About 144 adults aged 18-80 will take par…
Phase 4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug duo aims to shrink tough lung cancer in 33-patient trial
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good perfor…
Phase 2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Second-line hope: regorafenib tested after lenvatinib failure in liver cancer
Disease control Not yet recruitingThis study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…
Phase 2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for liver cancer patients with liver damage: drug tested after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…
Phase 2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to slash liver cancer recurrence after surgery
Disease control Not yet recruitingThis study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Simple vitamins may shield kidneys from chemo damage, new study suggests
Disease control Not yet recruitingThis study tests whether taking vitamin C and coenzyme Q10 can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 75 adults with various cancers who have not had chemo before will take these supplements alongside their treatment. The goal is to see i…
Phase 2/3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New Low-Cost radiation therapy could make liver cancer treatment accessible for all
Disease control Not yet recruitingThis study tests a new, affordable type of radioactive microsphere for treating liver cancer that cannot be removed by surgery. The microspheres are delivered directly to the tumor through a blood vessel, delivering radiation to kill cancer cells. The trial will enroll 18 adults …
Phase 1 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to make inoperable bile duct cancer eligible for transplant
Disease control Not yet recruitingThis phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that can…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for bile duct cancer: combo therapy aims to boost survival
Disease control Not yet recruitingThis study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…
Phase 2/3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could amino acids boost liver cancer treatment?
Disease control Not yet recruitingThis phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Liver cancer breakthrough? study tests surgery vs. drug maintenance after successful initial therapy
Disease control Not yet recruitingThis study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Thyroid cancer trial tests faster hormone control after radioiodine
Disease control Not yet recruitingThis study will enroll 40 people with high-risk differentiated thyroid cancer who need radioactive iodine therapy. After stopping their own thyroid hormones, participants will receive either standard levothyroxine alone or levothyroxine plus liothyronine. The goal is to see which…
Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for tough lung cancer: drug combo targets tumors after first treatment fails
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 people with extensive-stage small cell lung cancer whose disease got worse after initial chemotherapy plus immunotherapy. The goal is to see if the combo can shrink tumors or slow cancer gro…
Phase 2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Blue dye could make thyroid cancer surgery safer and more precise
Disease control Not yet recruitingThis study tests whether injecting a blue dye called mitoxantrone hydrochloride into the thyroid during robotic surgery helps surgeons see and remove cancer-affected lymph nodes while avoiding the parathyroid glands. 114 people with papillary thyroid cancer will be randomly assig…
Phase 4 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New trial matches liver cancer treatment to Tumor's Fat-Burning signature
Disease control Not yet recruitingThis phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …
Phase 2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Blocking blood flow before surgery may help remove inoperable bile duct cancer
Disease control Not yet recruitingThis study tests whether blocking the artery that feeds a bile duct tumor before surgery can make it possible to remove the cancer safely. It includes 33 adults with advanced bile duct cancer that currently cannot be operated on. The main goal is to see how many patients are aliv…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Promising new combo aims to extend life in rare, Tough-to-Treat cancer
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. Th…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for advanced liver cancer: drug trial targets patients with limited options
Disease control Not yet recruitingThis phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…
Phase 2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cocktail of pills plus procedure aims to fight untreatable liver cancer
Disease control Not yet recruitingThis study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly a…
Phase 2/3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug aims to fix Immunotherapy's blood problems in lung cancer
Disease control Not yet recruitingThis phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…
Phase 2 • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy aims to fix TSH suppression in thyroid cancer
Disease control Not yet recruitingThis phase 3 trial tests whether combining desiccated thyroid extract (DTE) with standard levothyroxine can help intermediate-to-high risk thyroid cancer patients reach their TSH suppression targets faster and more safely after surgery. Many patients on levothyroxine alone strugg…
Phase 3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Zapping liver cancer: electric pulses target tumors, spare healthy tissue
Disease control Not yet recruitingThis study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to se…
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Electric pulses zapping liver tumors: new hope for colorectal cancer patients?
Disease control Not yet recruitingThis study tests a procedure called irreversible electroporation (IRE), also known as Nanoknife, to treat liver tumors that have spread from colorectal cancer. IRE uses short electrical pulses to destroy cancer cells while sparing nearby blood vessels and bile ducts. The trial wi…
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Liver cancer breakthrough: surgery or pills after shrinkage?
Disease control Not yet recruitingThis study looks at patients with advanced liver cancer that cannot be removed by surgery at first. They receive a combination of treatments—chemotherapy directly into the liver, anti-angiogenic drugs, and immunotherapy—to shrink the tumor. If the tumor shrinks enough to become r…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase 1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New hope for liver cancer: drug targets tumors resistant to immunotherapy
Disease control Not yet recruitingThis phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers tha…
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 26, 2026 12:37 UTC
-
New drug cocktail aims to fight tough bile duct cancer
Disease control Not yet recruitingThis study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangi…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 12:36 UTC
-
New PET tracer aims to light up hidden cancer targets
Diagnosis Not yet recruitingResearchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…
Early phase 1 • Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can a new tracer reveal hidden tumors?
Diagnosis Not yet recruitingThis trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …
Early phase 1 • Sponsor: Lumina Pharmaceuticals Inc • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
Can AI be a second pair of eyes for liver cancer detection?
Diagnosis Not yet recruitingThis trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…
Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
New PET tracer may reveal which bile duct cancers resist standard therapy
Diagnosis Not yet recruitingThis trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…
Phase 2 • Sponsor: University of Washington • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
AI could spot hidden cancers on routine CT scans
Diagnosis Not yet recruitingThis study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…
Sponsor: Lian Yang • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
A simple breath test might spot multiple cancers before symptoms appear
Diagnosis Not yet recruitingThis trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a new imaging tracer outperform standard scans in finding hidden tumors?
Diagnosis Not yet recruitingThis trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New ultrasound technique could reveal hidden blood vessels in liver tumors
Diagnosis Not yet recruitingThis study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …
Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging agent aims to sharpen cancer detection
Diagnosis Not yet recruitingThis early-phase study tests a new radioactive imaging probe that targets a protein called FAP, found on many solid tumors. The probe is used with PET or SPECT scans to see if it can better locate tumors and determine if they have spread, compared to standard FDG-PET imaging. The…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis Not yet recruitingThis early-phase study tests a new radioactive tracer called [68Ga]Ga-FFD for PET imaging in healthy volunteers and people with solid tumors. The goal is to see if it is safe, where it goes in the body, and how well it spots tumors compared to standard imaging. Researchers will a…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Breath of discovery: simple test may sniff out lung cancer
Diagnosis Not yet recruitingThis pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New imaging agent aims to light up hidden tumors
Diagnosis Not yet recruitingThis early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …
Phase 1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New imaging agent could sharpen lung cancer detection
Diagnosis Not yet recruitingThis early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…
Early phase 1 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New scope may spot bile duct cancer faster
Diagnosis Not yet recruitingThis study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.
Sponsor: David KARSENTI • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New imaging agent could improve detection of rare cancers
Diagnosis Not yet recruitingThis study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New scan aims to spot liver cancer more clearly
Diagnosis Not yet recruitingThis study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New blood test aims to catch liver cancer recurrence early
Diagnosis Not yet recruitingThis study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…
Sponsor: Tongji Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New imaging agent could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…
Early phase 1 • Sponsor: Zhongnan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
New device could help save preterm babies by spotting oxygen drops
Diagnosis Not yet recruitingThis study tests a new light-based monitor (NIRS) that checks oxygen levels in the abdomen of preterm infants. Researchers want to see if it works reliably and safely on 50 babies born before 35 weeks. If it does, it could help doctors quickly detect life-threatening gut problems…
Sponsor: Carag AG • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
Liver protein TREM-1 may predict steroid response in alcoholic hepatitis
Diagnosis Not yet recruitingThis study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver disease…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 26, 2026 18:14 UTC
-
One extra therapy session may keep cancer patients off cigarettes
Prevention Not yet recruitingResearchers at Vietnam National Cancer Hospital are testing whether adding one structured cognitive behavioral therapy (CBT) session to standard brief counseling helps cancer patients remain smoke-free. The trial enrolls 498 adults who smoked at cancer diagnosis and have stayed c…
Sponsor: Vietnam National Cancer Hospital • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Ancient acupoint therapy may speed bowel recovery after liver surgery
Prevention Not yet recruitingThis trial tests whether stimulating specific acupoints—using herbal patches or mild electrical pulses—can help the bowels recover more quickly after liver cancer surgery. Patients scheduled for partial liver removal will be randomly assigned to one of four groups: herbal patches…
Sponsor: Shanghai Zhongshan Hospital • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Ear acupressure: a new weapon against chemotherapy side effects?
Prevention Not yet recruitingThis trial tests whether adding auricular acupressure—using small seed patches on specific ear points—to standard antiemetic medication can better prevent nausea and vomiting in people receiving highly emetogenic chemotherapy. About 332 patients with solid tumors will be randomly…
Sponsor: China Medical University, China • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Exercise may shield cancer Patients' hearts from chemo damage
Prevention Not yet recruitingThis study will test whether a 12-week program of supervised aerobic and strength exercises can prevent heart problems in 60 adults undergoing chemotherapy for cancer. Participants will be split into an exercise group and a usual-care group. Researchers will measure heart functio…
Sponsor: Federal University of Maranhao • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Low-Dose erlotinib aims to stop liver cancer before it starts
Prevention Not yet recruitingThis phase II trial tests whether a low dose of the cancer drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will take either erlotinib or a placebo daily for a set period. The study will measure changes in a blood protei…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Daily aspirin may slash liver cancer risk in cirrhosis patients
Prevention Not yet recruitingThis study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check…
Phase 3 • Sponsor: Curtin University • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Natural compound SAMe tested to block liver cancer in High-Risk patients
Prevention Not yet recruitingThis study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…
Phase 2 • Sponsor: Cedars-Sinai Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
A single zoom class might ease cancer pain for american indians
Symptom relief Not yet recruitingThis trial tests whether a single, two-hour online class called Empowered Relief can help American Indian adults with cancer-related pain. Participants learn three pain relief skills, create a personal plan, and get access to a free audio app for daily practice. The study aims to…
Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a video game teach cancer patients to tame their pain?
Symptom relief Not yet recruitingResearchers at Dana-Farber Cancer Institute are testing Healing Gardens, a mobile game that delivers pain-focused cognitive behavioral therapy and cancer pain education. The study enrolls 46 adults with advanced solid tumors who have chronic pain related to cancer or its treatmen…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can spiritual workshops ease Cancer's existential pain?
Symptom relief Not yet recruitingThis study tests a spiritual health program called PATH for cancer patients struggling with feelings of disconnection, loss of meaning, or existential distress. Twenty adults with any stage of cancer will attend six workshops combining role-playing, psychology, and dignity therap…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a single talk session help cancer patients quit smoking?
Symptom relief Not yet recruitingResearchers test whether adding one structured cognitive behavioral therapy session to standard brief quit-smoking advice helps cancer patients stop smoking. The trial enrolls 446 adults with cancer in Vietnam who smoked at diagnosis and still smoke. Everyone gets brief counselin…
Sponsor: Nguyen Duc Khoa, MD, PhD • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a single psychedelic dose ease despair in advanced cancer?
Symptom relief Not yet recruitingResearchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can coloring mandalas improve life for cancer patients?
Symptom relief Not yet recruitingResearchers are testing whether mandala coloring can improve quality of life for people receiving cancer care. The trial enrolls 76 hospitalized cancer patients and assigns them to either a coloring group or a routine-care group. For three weeks, the coloring group uses a mandala…
Sponsor: Emine TARLABELEN KARAYTUĞ • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can everyday moisturizers soothe cancer Therapy's skin toll?
Symptom relief Not yet recruitingThis trial tests whether cosmeceutical moisturizers can ease skin dryness in people with cancer who experience skin side effects from treatments like chemotherapy or immunotherapy. Participants apply the moisturizers daily for 2-4 weeks and report changes in dryness severity. The…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a smartphone app improve cancer care? new study tests personalized nutrition and activity guidance
Symptom relief Not yet recruitingThis study will test whether a mobile app called RestoreMe can help cancer patients get personalized nutrition and activity advice. Researchers plan to enroll 150 adults who are about to start, are currently receiving, or have completed cancer treatment. Participants will use the…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
Symptom relief Not yet recruitingThis pilot trial tests whether a program of virtual ukulele lessons, called STRUM, can help teenagers preserve cognitive function and emotional resilience while undergoing radiation therapy for cancer. The study enrolls adolescents aged 12 to 17 who are receiving initial radiatio…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a chatbot and VR headset lower stress in cancer wards?
Symptom relief Not yet recruitingResearchers are testing a digital tool called Mindbot, a chatbot on the LINE messaging app that guides hospitalized cancer patients through a 10-minute mindfulness session with breathing exercises and virtual reality. The trial enrolls 66 adults with cancer who are staying in the…
Sponsor: Taipei Medical University • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
A simple relaxation technique may ease the heavy anxiety of parents facing childhood cancer
Symptom relief Not yet recruitingThis trial tests whether progressive muscle relaxation, a technique where you tense and then relax different muscle groups, can lower anxiety in parents who are the primary caregivers of children with cancer. Researchers will randomly assign 112 parents to either join relaxation …
Sponsor: Akdeniz University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a Sleep-Themed game help chemo patients rest better?
Symptom relief Not yet recruitingResearchers are testing whether a web-based game that teaches sleep hygiene can improve sleep quality and reduce fatigue in people receiving chemotherapy. The trial enrolls 56 adults undergoing chemotherapy who do not have a diagnosed sleep disorder. Half receive the gamified Sle…
Sponsor: Lokman Hekim University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New radiation method aims to shrink large tumors
Symptom relief Not yet recruitingThis pilot study tests whether adding a specialized radiation technique called Lattice Radiation Therapy (LRT) to standard palliative radiation can safely shrink large tumors (at least 4.5 cm) in adults. The study will enroll 25 people with various cancers who are already schedul…
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Can fermented foods and fiber calm the side effects of immunotherapy?
Symptom relief Not yet recruitingThis pilot study tests whether changing the diet can improve gut health and help people with solid tumors recover from immune-related side effects caused by immune checkpoint inhibitor treatment. Participants are randomly assigned to eat a high-fermented food diet or take a resis…
Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
A good Night's sleep after cancer: can tailored Mind-Body training deliver?
Symptom relief Not yet recruitingResearchers are testing two behavioral programs to help Hispanic cancer survivors with insomnia. One combines gentle movement, meditation, and breathing. The other uses cognitive behavioral therapy for insomnia. Both are being culturally adapted with input from survivors. The stu…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can cannabis compounds help cancer patients sleep better?
Symptom relief Not yet recruitingThis study tests whether THC (with or without CBD) can improve sleep in people with solid organ cancer who have insomnia. About 69 participants will receive either THC, a THC/CBD mix, or a placebo as a liquid under the tongue. The goal is to see if these cannabis-based compounds …
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Yoga via zoom: a new way to calm anxiety in teens facing cancer?
Symptom relief Not yet recruitingThis study tests whether a four-week online yoga program, tailored to each teen's physical limits, can lower anxiety in adolescents aged 12 to 18 who are being treated for cancer. Participants either join the yoga sessions or receive no extra intervention, and researchers measure…
Sponsor: Akdeniz University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
AI assistant aims to ease thyroid cancer anxiety before surgery
Symptom relief Not yet recruitingThis study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meet…
Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
App aims to get cancer survivors moving again
Symptom relief Not yet recruitingThis study tests whether a smartphone app called the Cancer Exercise app (CEA) can help cancer survivors become more physically active. About 750 adults who have finished cancer treatment will either use the app for 12 weeks or receive usual care. The goal is to see if the app bo…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Could yoga ease the toll of stem cell transplants?
Symptom relief Not yet recruitingThis trial tests whether an inpatient yoga therapy program can improve quality of life and reduce symptoms like nausea, fatigue, and pain in cancer patients undergoing stem cell transplantation. Participants will be randomly assigned to either the yoga program or an enhanced stan…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can an AI chatbot ease the aftermath of cancer?
Symptom relief Not yet recruitingThis study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational su…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
Symptom relief Not yet recruitingMany cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and …
Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A new program aims to help teens thrive when a parent faces cancer
Symptom relief Not yet recruitingThis study is testing a family-centered program called SHINE, designed to support teenagers aged 10 to 17 who have a parent diagnosed with cancer. The program includes about four sessions over eight weeks, focusing on cancer education, family communication, coping skills, and emo…
Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Facing the fear: can talk therapy help couples live beyond cancer?
Symptom relief Not yet recruitingThis trial tests whether a type of talk therapy called Acceptance and Commitment Therapy (ACT) can help cancer survivors and their spouses cope with the fear that cancer might return. It compares ACT to a more traditional therapy, Cognitive Behavioural Therapy (CBT), in a two-arm…
Sponsor: University Center of Tumor Diseases, Frankfurt University Hospital • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Music may soothe pain at the genetic level after cancer surgery
Symptom relief Not yet recruitingThis study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can an AI chatbot ease fertility worries for young cancer survivors?
Symptom relief Not yet recruitingThis pilot trial tests whether a chatbot powered by large language models can help adolescent and young adult cancer survivors address reproductive concerns. Participants will be randomly assigned to use the chatbot or read an electronic brochure with similar information. The stu…
Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
A virtual pharmacy visit may ease opioid fears for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether a group telehealth session led by a palliative care pharmacist can help cancer patients better understand and manage their opioid pain medications. Many patients struggle with side effects, complex dosing, and fear of addiction, which can lead to un…
Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
A listening ear for cancer patients: can a care coordinator improve serious illness conversations?
Symptom relief Not yet recruitingThis trial tests whether a communication and care coordinator (CCC) can improve serious illness conversations and quality of life for adults with advanced or high-risk cancer. Participants in the intervention group will have six structured sessions over three months to discuss th…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
A personalized approach to breathlessness: could a stepped-care program offer relief for lung cancer patients?
Symptom relief Not yet recruitingShortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
A smartphone program aims to ease the emotional toll of fertility loss in young cancer survivors
Symptom relief Not yet recruitingThis trial tests whether a guided digital program delivered through a mobile app can reduce anxiety and depression in young adults (ages 18–40) who have fertility-related distress after a cancer diagnosis. Participants use the app to complete four modules covering coping skills, …
Sponsor: Gadjah Mada University • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Ice vs spray: which stops chemo mouth pain?
Symptom relief Not yet recruitingThis trial compares two simple treatments—sucking on ice chips or using a lidocaine spray—to see which better prevents or reduces painful mouth sores caused by chemotherapy. About 60 adults with cancer who are about to receive chemotherapy will be randomly assigned to one of the …
Sponsor: Hanady Jabbar Mahmood • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Belly button patch may fight cancer fatigue without drugs
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine patch placed on the belly button (Shenque acupoint) can reduce fatigue in cancer patients about to start radiotherapy. Eighty adults with cancer-related fatigue will receive either the real herbal patch or a sham patch daily…
Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
A simple tool may help thyroid cancer patients avoid treatment regret
Symptom relief Not yet recruitingMany people with small thyroid cancers can choose between a less extensive surgery (lobectomy) or a more extensive one (total thyroidectomy), yet some pick the riskier option without clear reason. This study tests whether an electronic decision navigation tool — one that highligh…
Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Money worries and cancer: can talking about both ease the burden?
Symptom relief Not yet recruitingThis pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
A scented soak for cancer symptoms: can lavender foot baths soothe pain and fatigue?
Symptom relief Not yet recruitingThis trial investigates whether daily aromatherapy foot baths with lavender essential oil can help cancer patients manage pain, sleep quality, and fatigue. Over five days, one group receives a 20-minute foot bath with lavender oil, while a control group receives routine care only…
Sponsor: Ankara Yildirim Beyazıt University • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
AI avatar could help cancer patients remember treatment details
Symptom relief Not yet recruitingThis trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…
Sponsor: Dr. Mark Mulder • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could an AI writing coach help chemo patients feel less anxious?
Symptom relief Not yet recruitingThis study tests whether an AI-assisted expressive writing program can reduce anxiety, emotional distress, and improve quality of life in adults receiving chemotherapy for any type of cancer. Participants are randomly assigned to either use the AI writing tool alongside their usu…
Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
New drug cocktail aims to stop Chemo-Linked nausea before it starts
Symptom relief Not yet recruitingThis study tests whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting caused by antibody-drug conjugates (ADCs) in cancer patients. Participants are adults with malignant tumors who have never received ADCs before and are about to st…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Could a comfort cart make cancer treatment easier for seniors?
Symptom relief Not yet recruitingThis study will test a comfort menu and cart for older adults (60+) receiving cancer treatment at a hospital in Brazil. The cart offers items like blankets, pillows, and hygiene kits to improve comfort. Researchers will compare patient and staff experiences before and after the c…
Sponsor: Hospital Sirio-Libanes • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a supplement beat cancer fatigue? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…
Sponsor: Canada Royal Enoch Phytomedicine Co., Ltd. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New program aims to ease financial burden for cancer patients
Symptom relief Not yet recruitingThis study tests a simple screening tool to identify cancer patients struggling with medical costs. Those who screen positive will be connected to financial counseling and resources at their hospital. The goal is to make it easier for patients to afford their care and reduce fina…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Warm blankets during surgery may shield Seniors' brains
Symptom relief Not yet recruitingThis study tests whether keeping older patients (65+) at a slightly higher body temperature (36.8°C) during major cancer surgery can reduce the risk of delayed neurocognitive recovery—a kind of short-term confusion or memory decline that can happen after surgery. About 1,500 part…
Sponsor: Peking University First Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a cannabis gummy be the key to better sleep for cancer patients?
Symptom relief Not yet recruitingThis study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…
Phase 1/2 • Sponsor: Theodore Brasky PhD • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a painless electrical patch help cancer patients sleep better after surgery?
Symptom relief Not yet recruitingThis study tests whether a non-invasive technique called transcutaneous electrical acupoint stimulation (TEAS) can prevent or treat sleep problems after cancer surgery. TEAS uses mild electrical pulses on specific points on the skin, based on acupuncture, without needles. The tri…
Sponsor: Second Hospital of Shanxi Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New stent technique may lower infection risk in bile duct cancer patients
Symptom relief Not yet recruitingThis study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…
Sponsor: Hospital de Clinicas de Porto Alegre • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Sophrology: a new way to calm radiation anxiety?
Symptom relief Not yet recruitingThis study tests whether sophrology, a relaxation technique using gentle movements, breathing, and positive visualization, can reduce anxiety in cancer patients undergoing radiation therapy. Fifty-four adults with various cancers will be offered sophrology sessions during their t…
Sponsor: Clinique Pasteur Lanroze • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Fasting during immunotherapy: a new way to boost treatment?
Symptom relief Not yet recruitingThis study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…
Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Exercise program aims to boost quality of life in young cancer patients
Symptom relief Not yet recruitingThis study tests whether a supervised strength training program can improve quality of life, physical function, and mental health in children with cancer. Twenty participants under 18 who are currently on treatment or dealing with after-effects will do two 50-minute sessions per …
Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Simple breathing and muscle relaxation may ease chemo sleep woes
Symptom relief Not yet recruitingThis study tests whether learning progressive muscle relaxation and deep breathing exercises can improve sleep for cancer patients receiving chemotherapy. About 40 adults aged 40-60 with poor sleep will be split into two groups: one gets relaxation training plus usual care, the o…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Medical cannabis studied as a remedy for chemo side effects
Symptom relief Not yet recruitingThis observational study will follow 50 people receiving chemotherapy that often causes nausea and vomiting. Researchers want to see if those who use medical cannabis on their own have less nausea, better appetite, and fewer other side effects compared to those who don't use it. …
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Online strength training tested to keep older cancer survivors moving
Symptom relief Not yet recruitingThis study tests whether live, online group strength training can help older cancer survivors (age 65+) who have trouble with daily activities. 150 participants will be split into three groups: immediate strength training, delayed strength training, or stretching. The goal is to …
Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Robot dog walks could ease fatigue in young cancer patients
Symptom relief Not yet recruitingThis study tests whether walking with a robot dog can improve sleep, reduce fatigue, and enhance quality of life in children aged 2-7 who are undergoing cancer treatment. Forty children will be randomly assigned to either robot-dog-assisted walks or usual care. The goal is to see…
Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Remote exercise program aims to boost chemo completion in cancer patients
Symptom relief Not yet recruitingThis study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…
Sponsor: AdventHealth Translational Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Acupuncture with a jolt: new trial tests electric needles for cancer brain fog
Symptom relief Not yet recruitingThis Phase 3 trial tests whether electroacupuncture—thin needles with mild electric pulses—can ease cognitive problems like memory loss and trouble focusing in cancer survivors. 168 participants will be assigned to real electroacupuncture, sham (fake) acupuncture, or a waitlist. …
Phase 3 • Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Weeding out stress: gardening program aims to boost cancer Survivors' Well-Being
Symptom relief Not yet recruitingThis study tests whether a 6-week gardening and nutrition program can improve quality of life for cancer survivors. Fifteen participants will attend weekly group sessions with gardening, cooking demos, and mindfulness. The main goal is to see if the program is practical and liked…
Sponsor: University of Vermont Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to help cancer patients reclaim joy and balance
Symptom relief Not yet recruitingThis study tests a group-based program for people with cancer that focuses on managing energy, doing meaningful activities, and improving quality of life. About 30 adults with cancer will take part in workshops and hands-on sessions in a community setting. The goal is to see if t…
Sponsor: University of Southern Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Horse power: equicoaching aims to rebuild social lives of young cancer survivors
Symptom relief Not yet recruitingThis study explores whether equicoaching—a type of coaching with horses—can help young adults (ages 15-25) who finished cancer treatment feel more confident and reconnect with others. Ten participants will take part in the program and share their experiences through interviews an…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Smartwatch data could ease cancer symptoms in new study
Symptom relief Not yet recruitingThis study tests whether a digital platform called Beacon can help doctors better manage symptoms in people with advanced cancer. About 40 patients will wear smartwatches and answer questions about how they feel. The platform combines this data to give doctors a clearer picture o…
Sponsor: Tzeela Cohen • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New online tool aims to ease Cancer's toll on patients and loved ones
Symptom relief Not yet recruitingThis study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…
Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Digital playtime therapy: helping kids with cancer move better
Symptom relief Not yet recruitingThis study tests a digital exercise program called EMPOWER for children aged 3 to 6 who are undergoing cancer treatment. The goal is to see if the program can help them stay physically active, improve their motor skills, and boost their quality of life. Parents and nurses will al…
Sponsor: Turku University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Cannabis oil trial aims to ease cancer Patients' daily suffering
Symptom relief Not yet recruitingThis study tests whether a cannabis extract oil containing THC and CBD can reduce the overall symptom burden in people with advanced solid tumors who are already taking strong painkillers. About 156 participants will receive either the cannabis oil or a placebo for 8 weeks. The m…
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Gut bacteria may help pancreatic surgery recovery
Symptom relief Not yet recruitingThis study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New web tool hopes to ease cancer Survivors' emotional struggles
Symptom relief Not yet recruitingThis pilot study tests an online program called Finding My Way-UK for people who finished curative cancer treatment in the past year. The program includes six self-guided modules on coping, emotions, and body image. Researchers will check if it's easy to use and if it helps with …
Sponsor: Edge Hill University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Virtual reality boosts brain power in cancer patients
Symptom relief Not yet recruitingThis study tests whether virtual reality (VR) exercises can improve memory and thinking in cancer patients who have cognitive problems. 64 participants will either use a VR program or receive standard care. The goal is to see if VR can help with brain fog and improve quality of l…
Sponsor: JING MINGXUE • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New stent placement method could reduce repeat procedures for bile duct cancer patients
Symptom relief Not yet recruitingThis trial tests a new way to place plastic stents in the bile duct for people with jaundice caused by cancer near the liver. The standard method places the stent across the bile duct opening, while the new method places it above the opening without cutting the muscle. The study …
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Could a smartphone app boost recovery before cancer surgery?
Symptom relief Not yet recruitingThis trial tests whether a smartphone app can help people improve their fitness before cancer surgery. 60 adults scheduled for elective cancer surgery will either use the app or receive usual care. The app guides them through weekly walking tests, daily check-ins on exercise, nut…
Sponsor: Korea University Anam Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Herbal pill may ease cancer treatment burden
Symptom relief Not yet recruitingThis study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 26, 2026 16:24 UTC
-
Can a smartwatch help cancer patients during chemo and radiation?
Knowledge-focused Not yet recruitingThis study will test whether cancer patients receiving chemotherapy and radiation therapy can use wearable health devices, like fitness trackers, to monitor their heart rate and activity levels. Twenty adults will wear the device during treatment and for four weeks after, uploadi…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Mapping how thyroid tumors spread and what surgery leaves behind
Knowledge-focused Not yet recruitingResearchers at Sohag University Hospitals are reviewing the medical records of 30 people treated for papillary thyroid cancer, the most common type of thyroid cancer. The study examines how far tumors extended beyond the thyroid gland and which complications appeared soon after s…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a video keep thyroid cancer patients on track after surgery?
Knowledge-focused Not yet recruitingAfter thyroid surgery for differentiated thyroid cancer, patients often need to take thyroid hormone at doses that keep TSH in a specific target range. Researchers at West China Hospital are testing whether adding a short educational video to standard instructions helps patients …
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can Re-Assessing bile duct cancer treatment open the door to surgery?
Knowledge-focused Not yet recruitingResearchers at Karolinska University Hospital are following 900 people diagnosed with intrahepatic or perihilar cholangiocarcinoma, two types of bile duct cancer. The study tracks how tumors respond to treatment, how patients feel and function, and changes in biomarkers over time…
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Thyroid surgery under the microscope: what 3,000 real operations reveal
Knowledge-focused Not yet recruitingResearchers at a Moscow medical center are studying the quality and outcomes of thyroid surgery using real-world clinical data. The study follows patients who had thyroid operations for benign or malignant disease, tracking complications, cancer results, and long-term outcomes. B…
Sponsor: Pirogov Russian National Research Medical University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
AI may help tailor cancer care for seniors, study puts it to the test
Knowledge-focused Not yet recruitingThis study tests whether a machine learning model called PROTEGER can help doctors choose the right cancer treatment for adults aged 65 and older with solid tumors. Researchers will train the model on past patient data, then check its accuracy in a new group of patients across Ch…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Doctors watch and learn: new study tracks endoscopy for pancreatic disease diagnosis
Knowledge-focused Not yet recruitingThis study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Personalized liver cancer treatment: a quest for predictive biomarkers
Knowledge-focused Not yet recruitingThis observational study follows 400 people with intermediate to advanced or unresectable hepatocellular carcinoma (the most common type of liver cancer) who are receiving systemic therapies such as atezolizumab plus bevacizumab or nivolumab plus ipilimumab, sometimes combined wi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
A deep dive into tumor markers could personalize lung cancer care
Knowledge-focused Not yet recruitingResearchers are collecting blood and tumor tissue samples from 30 adults with relapsed small-cell lung cancer who are receiving a standard DLL3 T cell engager therapy. The goal is to track changes in tumor markers over time and see if those changes relate to how well the treatmen…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a new model forecast liver cancer in hepatitis b?
Knowledge-focused Not yet recruitingThis study aims to build and test a model that predicts the risk of developing liver cancer (hepatocellular carcinoma) in people with hepatitis B-related liver fibrosis or cirrhosis. Researchers will analyze data from 2000 patients, including their medical history, blood sugar ma…
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can a simple checklist boost recovery after cancer surgery?
Knowledge-focused Not yet recruitingThis pilot study tests whether surgeons will use a new set of timeline-specific guidelines designed to improve functional recovery after high-risk abdominal cancer surgery. Researchers will monitor how often surgeons follow the guideline in clinic. The goal is to see if such a to…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can targeted therapy combinations outperform standard drugs in tough thyroid cancer?
Knowledge-focused Not yet recruitingThis study looks at how patients with radioiodine-refractory differentiated thyroid cancer are treated in the real world after first-line therapy stops working. It will compare two approaches: a targeted combination (dabrafenib plus trametinib) guided by a specific gene mutation,…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Could a simple scan and blood test outsmart liver cancer?
Knowledge-focused Not yet recruitingThis study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …
Sponsor: D'Or Institute for Research and Education • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Blood test may foretell Radiation's toll on the gut
Knowledge-focused Not yet recruitingThis observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults b…
Sponsor: Wang Xinying • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Radon education program aims to empower cancer survivors and their communities
Knowledge-focused Not yet recruitingThis study tests whether a short educational presentation about radon can improve knowledge and encourage testing among cancer survivors, their caregivers, and family members. Participants attend a single session, either in person or online, led by a study staff member. The goal …
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New digital tool aims to help young cancer patients discuss fertility and relationships with doctors
Knowledge-focused Not yet recruitingThis study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…
Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Cancer Patients' decisions shaped by drug benefit uncertainties, study finds
Knowledge-focused Not yet recruitingThis study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, wh…
Sponsor: London School of Economics and Political Science • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Ancient wisdom meets modern oncology: can TCM body types forecast treatment side effects?
Knowledge-focused Not yet recruitingThis study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…
Sponsor: Affiliated Hospital of Chengde Medical University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
Knowledge-focused Not yet recruitingThis study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…
Sponsor: HAN GUANG • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Blood markers may forecast liver cancer treatment success
Knowledge-focused Not yet recruitingThis study investigates whether substances in the blood can predict how patients with advanced liver cancer respond to a combination of atezolizumab and bevacizumab. Researchers will analyze leftover blood samples from routine tests in 100 patients to look for patterns linked to …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Do cancer patients overestimate drug benefits? a trial puts communication to the test.
Knowledge-focused Not yet recruitingThis study asks whether adding overall survival data to standard progression-free survival information helps current or former cancer patients more accurately judge a new drug's survival benefit. Around 3,000 U.S. adults with a past or present cancer diagnosis will read about a h…
Sponsor: London School of Economics and Political Science • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
AI to predict heart damage from cancer treatments in major european study
Knowledge-focused Not yet recruitingThis study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
3D MRI scan may predict liver cancer treatment success
Knowledge-focused Not yet recruitingThis study investigates whether a specialized MRI scan called three-dimensional magnetic resonance elastography (3D-MRE) can predict how well patients with initially unresectable liver cancer will respond to conversion therapy. The scan measures the stiffness and other physical p…
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Can a smartwatch track how cancer treatment affects daily life?
Knowledge-focused Not yet recruitingThis study explores whether cancer patients undergoing treatment can use a smartwatch and smartphone surveys to report their quality of life and physical activity. Over 12 weeks, participants wear a smartwatch at least 10 hours a day and complete questionnaires at several time po…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
AI reads tumor slides: can computer scores predict who will do well?
Knowledge-focused Not yet recruitingThis study enrolls 1,000 adults with solid tumors, including breast cancer, who receive an AI-based pathology test as part of their routine care. Researchers will link the AI test results with short- and long-term health outcomes to see how well the scores predict prognosis and t…
Sponsor: Ataraxis AI, Inc. • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Caregiver burden under the microscope: study links patient frailty to carer well-being
Knowledge-focused Not yet recruitingThis study looks at how the health of older adults with cancer affects the quality of life of the people who care for them. Researchers will follow 116 patient-caregiver pairs for six months, using questionnaires to measure caregiver well-being and patient frailty. The goal is to…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New scan could spot hidden cancer left behind after liver surgery
Knowledge-focused Not yet recruitingThis study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers w…
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Can a simple blood test predict immunotherapy success?
Knowledge-focused Not yet recruitingThis study will collect blood samples from 100 adults with cancer who are starting immunotherapy. Researchers will analyze the samples to find patterns in immune cells and molecules that might predict how well the treatment works or if it causes side effects. The goal is to bette…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
3D liver stiffness scan could predict surgery risks
Knowledge-focused Not yet recruitingThis study explores whether a special 3D MRI scan, called magnetic resonance elastography, can measure liver stiffness and elasticity before surgery to predict the risk of liver failure afterward. Researchers will enroll 150 adults with liver cancer or liver metastases who are sc…
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
AI chatbot aims to simplify cancer survivorship care
Knowledge-focused Not yet recruitingThis study tests an AI-powered chatbot that automatically creates personalized survivorship care plans for adult cancer survivors. The chatbot uses information from electronic health records to generate a plan and answer patients' questions about it. Researchers want to see if th…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Smartwatch data could help predict cancer outcomes
Knowledge-focused Not yet recruitingThis study collects health data from Apple Watches and iPhones of 1,200 cancer patients to build a research database. The goal is to see if wearable data like activity and heart rate can help personalize cancer prognosis and treatment. Participants must have an Apple Health app a…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
AI could outshine standard tumor measurements to predict survival
Knowledge-focused Not yet recruitingThis study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Blood test may reveal hidden cancer spread without scans
Knowledge-focused Not yet recruitingThis study is testing whether a blood test can locate where colorectal cancer has returned or spread after surgery. Researchers are analyzing genetic markers in the blood to build a model that predicts whether a recurrence is local or distant. The goal is to improve early detecti…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Can a heart drug help doctors see liver cancer better?
Knowledge-focused Not yet recruitingThis study explores whether a special imaging technique called parenchymal blood volume (PBV) imaging can detect changes in blood flow within liver tumors after giving a drug called nitroglycerin. The drug is commonly used for heart conditions but may temporarily increase blood f…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Could your body shape predict radiation accuracy?
Knowledge-focused Not yet recruitingThis study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning…
Sponsor: Shijiazhuang People's Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test could reveal how lung cancer evolves during treatment
Knowledge-focused Not yet recruitingThis study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can exercise help cancer patients? new study aims to find out
Knowledge-focused Not yet recruitingThis study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Cancer combo therapy under the microscope: real-world study launched
Knowledge-focused Not yet recruitingThis study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a s…
Sponsor: Sichuan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could your job give you pancreatic cancer? new study investigates
Knowledge-focused Not yet recruitingThis study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a simple ultrasound spot muscle loss in liver disease?
Knowledge-focused Not yet recruitingThis observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Too much info weighing on cancer patients? new study investigates
Knowledge-focused Not yet recruitingThis study looks at how feeling overwhelmed by information and dealing with symptoms affects the sense of empowerment in 300 adult cancer patients getting outpatient chemotherapy. Researchers will use surveys to measure information overload, symptom severity, and empowerment leve…
Sponsor: University of Yalova • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to predict immunotherapy success in cancer patients
Knowledge-focused Not yet recruitingThis study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions abou…
Sponsor: Sichuan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New blood test may predict infection risk after liver transplant
Knowledge-focused Not yet recruitingThis study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a digital Pre-Surgery boost help cancer patients recover faster?
Knowledge-focused Not yet recruitingThis study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…
Sponsor: Ludwig Boltzmann Institute for Digital Health and Prevention • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can blood tests and scans track lymphoma in real time? new study aims to find out.
Knowledge-focused Not yet recruitingThis study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …
Sponsor: The Lymphoma Academic Research Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can exercise become a standard part of cancer treatment? new study aims to find out
Knowledge-focused Not yet recruitingThis study looks at the best ways to add supervised exercise programs into standard cancer care. Researchers will track how often doctors refer patients to exercise and how many patients take part. The goal is to see if this approach is practical and helps improve patients' physi…
Sponsor: Melanie Keats • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to refine who gets a liver transplant for cancer
Knowledge-focused Not yet recruitingThis study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Massive study to uncover cancer Therapy's hidden toll on fertility
Knowledge-focused Not yet recruitingThis large observational study will follow 4,000 young cancer survivors (ages 15-39) across Europe to understand how different cancer treatments impact fertility, hormone function, and pregnancy outcomes. Researchers will also evaluate the safety and success of fertility preserva…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Major study to uncover cancer Treatment's hidden toll on fertility
Knowledge-focused Not yet recruitingThis study will follow 3,000 young women (ages 15-39) with cancer to understand how treatments like chemotherapy and immunotherapy impact their fertility, pregnancy outcomes, and quality of life. Researchers will also look at the safety and success of fertility preservation metho…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study aims to predict fertility problems in young men after cancer treatment
Knowledge-focused Not yet recruitingThis study follows 1,000 young men (ages 15-39) diagnosed with cancer to understand how treatments affect their fertility and hormone levels over time. Researchers will collect medical history, semen samples, and blood tests before and after therapy to identify who is at risk for…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can men still become dads after cancer? new study investigates
Knowledge-focused Not yet recruitingThis study will survey about 950 men who stored sperm at a French fertility center before cancer treatment between 2010 and 2024. Researchers want to know how many later became fathers, whether naturally or with medical help, and if they used their frozen sperm. The goal is to be…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study aims to spot muscle decline in cancer patients early
Knowledge-focused Not yet recruitingThis study will track muscle deterioration in about 40 hospitalized cancer patients using simple tests like grip strength, electrical muscle readings, and body composition scans. Researchers hope to find patterns that help identify muscle loss early, which could lead to better su…
Sponsor: University of Salamanca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New Real-Time imaging could make radiation therapy more precise
Knowledge-focused Not yet recruitingThis study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …
Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Lifestyle tweaks may cut liver cancer risk, new study hints
Knowledge-focused Not yet recruitingThis study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Massive french study to reveal best way to harvest donor livers
Knowledge-focused Not yet recruitingThis large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the be…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
AI could help pick surgery or ablation for liver cancer patients
Knowledge-focused Not yet recruitingThis study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New camera part may sharpen cancer scans
Knowledge-focused Not yet recruitingThis study tests whether a new collimator (a filter that directs gamma rays) on a special camera can produce clearer whole-body images for cancer patients. About 18 adults with multiple known cancer lesions will receive standard scans using technetium-99m, lutetium-177, or iodine…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
1,000 patients to help unlock secrets of liver surgery recovery
Knowledge-focused Not yet recruitingThis study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…
Sponsor: Azienda USL Toscana Centro • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Cancer Patients' samples to fuel Tomorrow's discoveries
Knowledge-focused Not yet recruitingThis study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Chemo Patients' digital habits under the microscope
Knowledge-focused Not yet recruitingThis study looks at how adults getting chemotherapy use digital media and how well they understand online health information. Researchers will survey 80 patients about their digital habits and health literacy. The goal is to learn more so doctors can better support patients in us…
Sponsor: Fenerbahce University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to make repeat radiation safer for cancer patients
Knowledge-focused Not yet recruitingThis study will collect data from 500 Danish cancer patients who need repeat radiation therapy (reirradiation). Researchers will track side effects, tumor control, and survival to build a database that can guide safer treatment in the future. The goal is to help doctors decide wh…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Blood test may predict chemo nerve damage before it starts
Knowledge-focused Not yet recruitingThis study aims to find blood markers that can predict which cancer patients will develop chronic nerve pain from chemotherapy. Researchers will collect blood samples and perform neurological exams on 192 patients over 6 months. The goal is to use this information to personalize …
Sponsor: Centre Hospitalier de Bligny • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Old tumor samples may hold key to future biliary cancer treatments
Knowledge-focused Not yet recruitingThis study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …
Sponsor: MedSIR • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New study aims to predict dangerous immunotherapy side effects before they happen
Knowledge-focused Not yet recruitingThis study will collect blood and swab samples from 160 adults with solid tumors who are about to start immunotherapy. The goal is to find a biological 'signature' that can predict which patients will develop severe immune-related side effects. If such a signature is found, it co…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study to track brain health after CAR-T cancer treatment
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Does diabetes make cancer treatment harder? new study investigates
Knowledge-focused Not yet recruitingThis observational study looks at how having type 2 diabetes impacts quality of life in cancer patients receiving immunotherapy. Researchers will compare changes in well-being over six months between patients with and without diabetes. About 920 adults with solid tumors will fill…
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Blood tests and patient surveys could improve bile duct cancer monitoring
Knowledge-focused Not yet recruitingThis study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…
Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Virtual twins could unlock secrets of fatty liver and heart risk
Knowledge-focused Not yet recruitingThis study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…
Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Can early gene testing unlock better cancer treatments?
Knowledge-focused Not yet recruitingThis study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Blood test may replace scans for liver cancer treatment monitoring
Knowledge-focused Not yet recruitingThis study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…
Sponsor: University of Belgrade • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Massive study to uncover hidden mental toll of cancer
Knowledge-focused Not yet recruitingThis study aims to better understand psychiatric disorders, thinking problems, and treatment side effects in 2000 cancer patients and their close relatives. Researchers will compare those with and without mental health issues to find patterns and improve care. No new treatments a…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
AI and 3D imaging aim to revolutionize bile duct surgery
Knowledge-focused Not yet recruitingThis study aims to create a 3D model of the bile ducts using MRI and CT scans, along with an AI tool to help doctors guide a camera during a procedure called ERCP. The goal is to improve safety and accuracy. The study will use existing medical images from 100 adult patients who h…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Lung cancer drug anlotinib tested in Real-World review after treatment failure
Knowledge-focused Not yet recruitingThis study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Could a COVID shot boost cancer treatment? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Which ERCP rescue method is safer? major trial launches
Knowledge-focused Not yet recruitingThis trial compares two techniques used when standard bile duct access fails during ERCP: pre-cut sphincterotomy and the double guidewire technique. Researchers will enroll 840 adults with difficult bile duct cannulation to see which method is safer and more successful. The goal …
Sponsor: Asian Institute of Gastroenterology, India • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Protein fingerprint may forecast liver cancer 15 years early
Knowledge-focused Not yet recruitingThis study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Rare gene defect may fuel liver cancer in otherwise healthy livers
Knowledge-focused Not yet recruitingThis study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study tracks immune therapy results in advanced liver cancer
Knowledge-focused Not yet recruitingThis study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-w…
Sponsor: Ahmed Karam Helmy • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can a 30-minute bike ride help fight liver cancer? scientists investigate.
Knowledge-focused Not yet recruitingThis study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommenda…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New study aims to predict bleeding and clotting risks in cancer patients
Knowledge-focused Not yet recruitingThis observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Could Omega-6 fats signal liver cancer risk?
Knowledge-focused Not yet recruitingThis observational study will measure Omega-6 fatty acid levels in the blood of 100 adults — half with liver cancer and half without — to see if there is a connection. No drugs or treatments are given. The goal is to understand if these fats are linked to the presence or severity…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Thyroid microcancer study: surgery, heat ablation, or just watching?
Knowledge-focused Not yet recruitingThis study follows 1,630 people with a small, low-risk thyroid cancer to compare three management options: surgery, heat ablation (a minimally invasive procedure), or active surveillance (monitoring without immediate treatment). The goal is to see which approach offers the best s…
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Rare cervical cancer under the microscope: new study aims to unlock its secrets
Knowledge-focused Not yet recruitingThis study focuses on a rare and aggressive type of cervical cancer called large cell neuroendocrine carcinoma (LCNEC). Researchers will look back at medical records and follow 200 patients over time to understand the disease's behavior and what factors affect survival. The goal …
Sponsor: Lili • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Cancer patients' cannabis habits under the microscope
Knowledge-focused Not yet recruitingThis study will follow 45 cancer patients who use cannabis, asking them to log their use in a smartphone app. Researchers want to learn how often and why patients use cannabis, what forms they use, and what effects they notice. The goal is to gather real-world data to guide futur…
Sponsor: Scot Remick • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Blood particle test may predict liver failure and cancer risk
Knowledge-focused Not yet recruitingThis study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC